NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
TVTX
Travere Therapeutics, Inc.
TVTX has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TVTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Strong |
TVTX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TVTX PE Valuation
TVTX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TVTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TVTX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TVTX on earnings quality, reporting a profit while its opponent remains loss making.
TVTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.94 | — |
| Q3 2026 | -$1.28 | -$0.24 |
| Q2 2026 | -$0.45 | +$1.57 |
| Q1 2026 | -$0.22 | +$2.57 |
| Q4 2025 | -$0.29 | +$3.79 |
| Q3 2025 | -$1.04 | +$3.51 |
| Q2 2025 | -$2.02 | -$0.14 |
| Q1 2025 | -$2.79 | -$0.69 |
| Q4 2024 | -$4.08 | -$2.47 |
TVTX is still losing money, but far less than before: $1.28 per share over the past year, against $4.56 at its worst in late 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TVTX on profitability, with a higher operating margin.
TVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $224.6M | +36% |
| Q2 2026 | $169.6M | +48% |
| Q1 2026 | $127.2M | +56% |
| Q4 2025 | $129.7M | +73% |
| Q3 2025 | $164.9M | +162% |
| Q2 2025 | $114.4M | +111% |
| Q1 2025 | $81.7M | +98% |
| Q4 2024 | $74.8M | +66% |
TVTX has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | -45 points |
| Q2 2026 | 2.3% | +13 points |
| Q1 2026 | -29% | +23 points |
| Q4 2025 | -25% | +56 points |
| Q3 2025 | 15% | +104 points |
| Q2 2025 | -11% | +114 points |
| Q1 2025 | -52% | +284 points |
| Q4 2024 | -81% | +128 points |
TVTX's operating margin was −30% last quarter, down 45 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
TVTX has the stronger cash trend. Its trailing FCF is up 168% versus its history, compared with NVO at down 14%.
TVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$40.4M | +$1.8M |
| Q4 2025 | $60.7M | +$96.4M |
| Q3 2025 | $14.2M | +$56.7M |
| Q1 2025 | -$42.2M | +$76.8M |
| Q4 2024 | -$35.7M | +$34.8M |
| Q2 2024 | -$40.3M | +$29M |
| Q1 2024 | -$119M | -$37.3M |
| Q4 2023 | -$70.5M | -$15.8M |
TVTX's free cash flow has turned positive after five years mostly in the red: $93M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | -7.8% | -8M shares |
| 3 years | +24% | +18.3M shares |
| 5 years | +56% | +33.8M shares |
| Available history | +123% | +52.3M shares |
TVTX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TVTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -5.1x | Net Cash |
| Q1 2026 | -4.9x | Net Cash |
TVTX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 18.2 | Oversold |
TVTX's weekly RSI is 48 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TVTX PE vs Healthcare Sector
TVTX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.5 | 1.7% below |
| 20 week MA | $57.6 | 11% below |
| 50 week MA | $45.2 | 14% above |
| 100 week MA | $32.9 | 57% above |
| 200 week MA | $22.8 | 126% above |
TVTX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
TVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $27.6 | +92% |
| 2021 | $27.6 | $31.2 | +13% |
| 2022 | $31.2 | $20.0 | -36% |
| 2023 | $20.0 | $8.99 | -55% |
| 2024 | $8.99 | $17.3 | +92% |
| 2025 | $17.3 | $39.6 | +129% |
| 2026 YTD | $39.6 | $51.6 | +30% |
TVTX has the edge over NVO on returns for 2026, with the stronger performance.